Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Lactobacillus fermentum DR9 (LF-DR9) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 17/December/2018, 11.55 pm

RNA-based therapy for aging-associated diseases and Lifespan extension: LncRNA MALAT/NEAT2  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging, via down-regulation of its target gene, 17/January/2019, 11.48 pm
January 17, 2019
RNA-based therapy for aging-associated diseases and Lifespan extension: LncRNA UCA1  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging, via down-regulation of its target gene, 18/January/2019, 12.04 am
January 17, 2019
Show all

The significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


Research findings to Therapeutic opportunity:

This study suggests a probiotic-based therapy for lowering cholesterol and triglyceride levels and to treat Non-alcoholic fatty liver disease (NAFLD).

Lactobacillus fermentum DR9 (LF-DR9), by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, Lactobacillus fermentum DR9 (LF-DR9), either alone or in combination with other drugs, may be used to treat NAFLD.

Figure 1. Mechanistic insights into how Lactobacillus fermentum DR9 (LF-DR9) decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD.

Figure 2. Lactobacillus fermentum DR9 (LF-DR9) functions as a cholesterol-lowering agent. Lactobacillus fermentum DR9 (LF-DR9) lowers cholesterol and triglyceride levels and attenuates NAFLD, through down-regulation of HMGCR

[easy_payment currency=”USD”]


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Lactobacillus fermentum DR9 (LF-DR9) decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Lactobacillus fermentum DR9 (LF-DR9) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 17/December/2018, 11.55 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, kindly drop us a line at info@genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.